ACAngelo Cabal

Angelo Cabal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Angelo Cabal has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Rana R. McKay

    Division of Medical Oncology University of California, San Diego Moores Cancer Center San Diego California USA

    2 shared publications
  • Assuntina Sacco

    University of California San Diego Moores Cancer Center La Jolla California USA

    1 shared publication
  • Francesca J. Torriani

    University of California San Diego

    1 shared publication
  • Ithaar H. Derweesh

    Department of Urology, University of California San Diego, La Jolla, CA

    1 shared publication
  • Joseph A. Califano

    Affiliations Moores Cancer Center, UC San Diego, La Jolla, California United States of America, Department of Otolaryngology-Head and Neck Surgery, UC San Diego School of Medicine, San Diego, California, United States of America, Gleiberman Head and Neck Cancer Center, UC San Diego, La Jolla, California, United States of America

    1 shared publication
  • Justin A. Shaya

    Department of Medicine, Division of Hematology-Oncology, University of California San Diego, La Jolla, CA

    1 shared publication

Latest Publications

  • Prognostic Significance of Pancreatic Metastases in Patients With Advanced Renal Cell Carcinoma Treated With Systemic Therapy

    by Justin A. Shaya, Xun Lin, Nicole Weise, Angelo Cabal, Justine Panian, Ithaar H. Derweesh, Rana R. McKay


  • Open Access

    Asymptomatic detection of SARS‐CoV‐2 among cancer patients receiving infusional anti‐cancer therapy

    by Justin Shaya, Angelo Cabal, Taylor Nonato, Francesca Torriani, Joseph Califano, Scott Lippman, Assuntina Sacco, Rana R. McKay

    Background: Little is known regarding the rate and clinical outcomes of asymptomatic carriers of SARS‐CoV‐2 among patients with cancer. Detection of asymptomatic carriers is important in this population given the use of myelosuppressive and immunomodulating therapies. Understanding the asymptomatic carrier rate will help to develop mitigation strategies in this high‐risk cohort.Methods: Retrospective cohort analysis of an asymptomatic screening protocol which required patients receiving infusional anti‐cancer therapy to undergo a symptom/exposure screen and SARS‐CoV‐2 PCR testing 24–96 h prior to their infusion. The primary outcome of this analysis was the rate of asymptomatic SARS‐CoV‐2 infection. Secondary outcomes included the rate of COVID‐19‐related hospitalization and mortality and delays in oncologic therapy.Results: Among a cohort of 2691 cancer patients who underwent asymptomatic screening, 1.6% (N = 43/2691) of patients were found to be SARS‐CoV‐2 positive on asymptomatic screening. 11.6% (N = 5/43) of the cohort ultimately developed COVID‐19‐related symptoms. Four patients required hospitalization for complications of COVID‐19 infection. No patient died from COVID‐related complications. 97.7% (N = 42/43) had their anti‐cancer therapy delayed or deferred with a median delay of 21 days (range: 7–77 days).Conclusions: Overall, among a cohort of active cancer patients receiving anti‐cancer therapy, an asymptomatic SARS‐CoV2 PCR‐based screening protocol detected a small cohort of asymptomatic carriers. The majority of these patients remained asymptomatic on long‐term follow‐up and outcomes were much more favorable compared to previously described outcomes of cancer patients with symptomatic COVID‐19 infection.